Through the voices of some of our longest-serving team members, we look back at The Max Foundation’s decades-long cancer treatment access partnership with Novartis. For more than a quarter century, The Max Foundation (Max) and Novartis have been working together with a shared purpose: accelerating health equity, one patient at a time. What began as….
This year, we’re celebrating 25 years of partnership with Novartis. Together, we’ve provided access to treatment for more than 100,00 people living with cancer in low- and middle-income countries. Below, eight patients from four locations where we operate share their stories. They talk about how they were diagnosed, the impact of having treatment, and what’s….
Introducing Dr. Aitbu Amankulova from Kyrgyzstan! She has worked as an oncologist-hematologist for more than 10 years and has been a Max partner physician since 2025. Learn more about her below. Describe a typical work week: My workdays are filled with patient consultations, follow-up care, medical documentation, and communication with colleagues. Every day is different….
In 2001, The Max Foundation partnered with the pharmaceutical corporation Novartis to develop an international treatment access program for people living with chronic myeloid leukemia (CML). Since then, we’ve helped thousands of patients in low- and middle-income countries access life-extending diagnostics, medication, and support services. A lot has changed over the years, but our focus….
A man once sat across from Dr. Pritanjali Singh shortly after being diagnosed with chronic myeloid leukemia (CML). He was frightened, not only about his health, but also about something equally important to him: how he would continue supporting his family. Years later, he walked back into her clinic. This time, he wasn’t afraid. Instead,….
Introducing Dr. Johanna Rapanarilala from Seychelles! She has worked as an oncologist for more than 20 years and has been a Max partner physician since 2012. Learn more about her below. Describe a typical work week From Monday to Friday, I start at 7 a.m. with a review of my daily plan. Followed by ward….
By Dr. Mipsang Lama Partner Physician at Patan Hospital in Nepal When Treatment Feels Like a Miracle Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and devastating blood disorder. In many high-income countries, it is a condition with established treatment pathways. But in Nepal, for years, it was something we could diagnose, yet not truly treat…..
Introducing Dr. Beatriz Moiraghi! She has worked as a hematologist for 25 years in Argentina and has been a Max partner physician since 2002. Learn more about her below. Describe a typical work week: On a typical workday, I arrive at the hospital early, at 7 a.m. I not only see patients from the Max….
At The Max Foundation we are all about patients; deeply, profoundly, committed to patients and by extension their families and communities. To continue to foster this commitment, once a year we honor a team member who has exemplified our values and beliefs with the Excellence in Patient Advocacy Award. We are proud to announce the….
Today we remember Dr. Damira Bayzakova, a CML specialist and cancer advocate from Kyrgyzstan who passed away on November 16th 2020, due to complications with COVID-19. Dr. Bayzakova was an implementing partner for The Max Foundation since 2006, and was monumental in bringing life-saving treatment and cancer diagnostics into Kyrgyzstan. Dr. Bayzakova’s efforts to expand….
All of us at The Max Foundation are wholly committed to maximizing every opportunity to collaborate and build new partnerships on behalf of the patients we serve in low resource settings. We are excited to move onward to a new chapter with innovative opportunities to expand our impact. We hope you will see a place for yourself to join us in this effort to close the cancer divide!
A “cold-chain” product must remain within a specific temperature range at all times. On days- or weeks-long international shipments, it’s especially challenging (and expensive) to keep medicine at a constant temperature. Despite the inherent challenges, adding cold-chain capability is well worth the effort for the patients we support. By doing so, The Max Foundation will be able to better meet the needs of patients who are unresponsive to tablet therapies.
